vs
Embecta Corp.（EMBC）与PROGRESS SOFTWARE CORP（PRGS）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是PROGRESS SOFTWARE CORP的1.0倍（$261.2M vs $252.7M），Embecta Corp.净利率更高（16.9% vs 10.2%，领先6.7%），PROGRESS SOFTWARE CORP同比增速更快（17.5% vs -0.3%），PROGRESS SOFTWARE CORP自由现金流更多（$59.9M vs $16.6M），过去两年PROGRESS SOFTWARE CORP的营收复合增速更高（17.0% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
EMBC vs PRGS — 直观对比
营收规模更大
EMBC
是对方的1.0倍
$252.7M
营收增速更快
PRGS
高出17.8%
-0.3%
净利率更高
EMBC
高出6.7%
10.2%
自由现金流更多
PRGS
多$43.3M
$16.6M
两年增速更快
PRGS
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $252.7M |
| 净利润 | $44.1M | $25.7M |
| 毛利率 | 61.9% | 81.6% |
| 营业利润率 | 31.9% | 15.2% |
| 净利率 | 16.9% | 10.2% |
| 营收同比 | -0.3% | 17.5% |
| 净利润同比 | — | 2144.6% |
| 每股收益（稀释后） | $0.74 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCPRGS
| Q4 25 | $261.2M | $252.7M | ||
| Q3 25 | $264.0M | $249.8M | ||
| Q2 25 | $295.5M | $237.4M | ||
| Q1 25 | $259.0M | $238.0M | ||
| Q4 24 | $261.9M | $215.0M | ||
| Q3 24 | $286.1M | $178.7M | ||
| Q2 24 | $272.5M | $175.1M | ||
| Q1 24 | $287.2M | $184.7M |
净利润EMBCPRGS
| Q4 25 | $44.1M | $25.7M | ||
| Q3 25 | $26.4M | $19.4M | ||
| Q2 25 | $45.5M | $17.0M | ||
| Q1 25 | $23.5M | $10.9M | ||
| Q4 24 | $0 | $1.1M | ||
| Q3 24 | $14.6M | $28.5M | ||
| Q2 24 | $14.7M | $16.2M | ||
| Q1 24 | $28.9M | $22.6M |
毛利率EMBCPRGS
| Q4 25 | 61.9% | 81.6% | ||
| Q3 25 | 60.0% | 81.0% | ||
| Q2 25 | 66.7% | 80.1% | ||
| Q1 25 | 63.4% | 80.6% | ||
| Q4 24 | 60.0% | 83.0% | ||
| Q3 24 | 60.7% | 83.7% | ||
| Q2 24 | 69.8% | 81.7% | ||
| Q1 24 | 64.6% | 82.2% |
营业利润率EMBCPRGS
| Q4 25 | 31.9% | 15.2% | ||
| Q3 25 | 21.4% | 17.6% | ||
| Q2 25 | 31.8% | 16.3% | ||
| Q1 25 | 24.3% | 13.6% | ||
| Q4 24 | 11.0% | 10.0% | ||
| Q3 24 | 9.2% | 22.6% | ||
| Q2 24 | 20.5% | 15.5% | ||
| Q1 24 | 13.6% | 19.0% |
净利率EMBCPRGS
| Q4 25 | 16.9% | 10.2% | ||
| Q3 25 | 10.0% | 7.8% | ||
| Q2 25 | 15.4% | 7.2% | ||
| Q1 25 | 9.1% | 4.6% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | 5.1% | 15.9% | ||
| Q2 24 | 5.4% | 9.2% | ||
| Q1 24 | 10.1% | 12.3% |
每股收益（稀释后）EMBCPRGS
| Q4 25 | $0.74 | $0.59 | ||
| Q3 25 | $0.44 | $0.44 | ||
| Q2 25 | $0.78 | $0.39 | ||
| Q1 25 | $0.40 | $0.24 | ||
| Q4 24 | $0.00 | $0.01 | ||
| Q3 24 | $0.24 | $0.65 | ||
| Q2 24 | $0.25 | $0.37 | ||
| Q1 24 | $0.50 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $94.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $-613.1M | $478.3M |
| 总资产 | $1.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 2.93× |
8季度趋势，按日历期对齐
现金及短期投资EMBCPRGS
| Q4 25 | $201.3M | $94.8M | ||
| Q3 25 | $225.5M | $99.0M | ||
| Q2 25 | $230.6M | $102.0M | ||
| Q1 25 | $209.3M | $124.2M | ||
| Q4 24 | $210.0M | $118.1M | ||
| Q3 24 | $267.5M | $232.7M | ||
| Q2 24 | $275.1M | $190.4M | ||
| Q1 24 | $299.8M | $133.2M |
总债务EMBCPRGS
| Q4 25 | — | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCPRGS
| Q4 25 | $-613.1M | $478.3M | ||
| Q3 25 | $-650.6M | $477.7M | ||
| Q2 25 | $-669.6M | $452.7M | ||
| Q1 25 | $-736.2M | $431.8M | ||
| Q4 24 | $-768.8M | $438.8M | ||
| Q3 24 | $-738.3M | $425.6M | ||
| Q2 24 | $-763.7M | $401.7M | ||
| Q1 24 | $-769.6M | $461.7M |
总资产EMBCPRGS
| Q4 25 | $1.1B | $2.5B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.2B | $2.4B | ||
| Q1 25 | $1.1B | $2.5B | ||
| Q4 24 | $1.1B | $2.5B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.2B | $1.5B |
负债/权益比EMBCPRGS
| Q4 25 | — | 2.93× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 3.50× | ||
| Q4 24 | — | 3.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $62.8M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $59.9M |
| 自由现金流率自由现金流/营收 | 6.4% | 23.7% |
| 资本支出强度资本支出/营收 | 0.2% | 1.1% |
| 现金转化率经营现金流/净利润 | 0.39× | 2.44× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $229.5M |
8季度趋势，按日历期对齐
经营现金流EMBCPRGS
| Q4 25 | $17.2M | $62.8M | ||
| Q3 25 | $84.0M | $73.4M | ||
| Q2 25 | $81.2M | $30.0M | ||
| Q1 25 | $31.8M | $68.9M | ||
| Q4 24 | $-5.3M | $19.7M | ||
| Q3 24 | $26.6M | $57.7M | ||
| Q2 24 | $-2.1M | $63.7M | ||
| Q1 24 | $24.3M | $70.5M |
自由现金流EMBCPRGS
| Q4 25 | $16.6M | $59.9M | ||
| Q3 25 | $76.7M | $72.4M | ||
| Q2 25 | $80.8M | $29.5M | ||
| Q1 25 | $31.7M | $67.7M | ||
| Q4 24 | $-6.8M | $16.8M | ||
| Q3 24 | — | $56.6M | ||
| Q2 24 | $-11.8M | $62.7M | ||
| Q1 24 | $20.9M | $70.2M |
自由现金流率EMBCPRGS
| Q4 25 | 6.4% | 23.7% | ||
| Q3 25 | 29.1% | 29.0% | ||
| Q2 25 | 27.3% | 12.4% | ||
| Q1 25 | 12.2% | 28.4% | ||
| Q4 24 | -2.6% | 7.8% | ||
| Q3 24 | — | 31.7% | ||
| Q2 24 | -4.3% | 35.8% | ||
| Q1 24 | 7.3% | 38.0% |
资本支出强度EMBCPRGS
| Q4 25 | 0.2% | 1.1% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.6% | 1.3% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 3.6% | 0.5% | ||
| Q1 24 | 1.2% | 0.2% |
现金转化率EMBCPRGS
| Q4 25 | 0.39× | 2.44× | ||
| Q3 25 | 3.18× | 3.78× | ||
| Q2 25 | 1.78× | 1.76× | ||
| Q1 25 | 1.35× | 6.30× | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | 1.82× | 2.03× | ||
| Q2 24 | -0.14× | 3.93× | ||
| Q1 24 | 0.84× | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
